Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | PPOX | P50336 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192944 | 0.94 | FFAR1 (0.43) | FFAR1MEN1TTRPPOXKMT2A | |
| SCHEMBL10195182 | 0.89 | SLC6A4 (0.34) | HTR2ASLC6A4KCNH2PPARDPPARA | |
| SCHEMBL10195345 | 0.89 | THRB (0.40) | MRGPRX4HTR2ASLC6A4KCNH2 | |
| SCHEMBL10195115 | 0.88 | SLC6A4 (0.41) | HTR2ASLC6A4KCNH2PPARG | |
| SCHEMBL10195097 | 0.88 | HTR2A (0.39) | FFAR1TTRTDP1MRGPRX4HTR2A | |
| SCHEMBL10195200 | 0.87 | MMP14 (0.35) | FFAR1MEN1KMT2ASLC6A4PPARA | |
| SCHEMBL16181151 | 0.87 | HTR2A (0.36) | MRGPRX4HTR2ASLC6A4KCNH2PPARG | |
| SCHEMBL10195204 | 0.86 | AR (0.41) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL10195344 | 0.86 | MAPT (0.43) | MEN1TTRPPOXKMT2ATDP1 | |
| SCHEMBL10195077 | 0.86 | HTR2A (0.36) | MEN1KMT2ATDP1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387569-B1 | HERBCIDES | SYNGENTA LTD (GB) | 2016-06-15 | — | — | EP | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378305-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865623-B2 | Herbicidally active cyclic diones and derivatives thereof, processes for their preparation, compositions, and method of controlling weeds | SYNGENTA LIMITED (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021907-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378305-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | FFAR1 1022/4885MEN1 4216/4885TTR 2941/4885 |
| US-20120021907-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | FFAR1 752/4885MEN1 4280/4885TTR 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.